Opendata, web and dolomites
  1. home
  2. trasparenza
  3. open h2020
  4. sap-nano

SAP-Nano

A disruptive technology for vaccines manufacturing based on Self-Assembled Polymeric Nanoparticulate systems

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0
 Outcomes and results

 SAP-Nano project word cloud

Explore the words cloud of the SAP-Nano project. It provides you a very rough idea of what is the project "SAP-Nano" about.

detected    significantly    antigens    usd    feasibility    volatile    fish    strategies    manufacturer    submission    bionanoplus    standard    conventional    nano    patented    thorough    nmp    firstly    84    easily    nanotechnology    successfully    manufacturers    impossible    score    perform    laboratory    clients    viability    opportunity    instrument    avoiding    total    scalable    solved    plan    presented    industry    business    eur    verify    21    risks    issue    suitable    marketing    25    nanoparticle    sap    scalability    model    evaluation    664    point    move    industrial    prrsv    techniques    vaccines    usa    solvents    requirement    2015    veterinary    11    molecules    pharmaceutical    minimize    commercial    swine    12    billion    market    company    met    versatile    organic    launch    first    manufacturing    costly    million    time    inexpensive    economic    ensures    cosmetic    losses    seemed    performed    encapsulate    faced    sme    lower   

Project "SAP-Nano" data sheet

The following table provides information about the project.

Coordinator		 BIONANOPLUS SL 

Organization address
address: POLIGONO MOCHOLI, PLAZA CEIN 5
city: NOAIN
postcode: 31110
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.
 Coordinator Country Spain [ES]
 Project website http://www.bionanoplus.com
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.2.1.5. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies - Advanced manufacturing and processing)
2. H2020-EU.2.1.3. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies - Advanced materials)
3. H2020-EU.2.3.1. (Mainstreaming SME support, especially through a dedicated instrument)
4. H2020-EU.2.1.2. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies – Nanotechnologies)
 Code Call H2020-SMEINST-1-2016-2017
 Funding Scheme SME-1
 Starting year 2016
 Duration (year-month-day) from 2016-06-01   to  2016-11-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    BIONANOPLUS SL ES (NOAIN) coordinator 50˙000.00

Map

 Project objective

Bionanoplus detected the major problems faced by many pharmaceutical, veterinary and cosmetic sector manufacturers to develop products using nanotechnology. It seemed impossible and costly to move a product developed in the laboratory to the industrial manufacturing of the product. To solve this issue Bionanoplus has developed and patented a highly versatile and easily scalable technology to encapsulate antigens and other molecules, called SAP-Nano. Bionanoplus has solved the scalability problem of traditional nanoparticle manufacturing methods avoiding the use of volatile organic solvents, thus it ensures an easy and inexpensive production of any scale, which can be performed using standard equipment and techniques. SAP-Nano technology has been successfully implemented with two clients, a fish vaccines manufacturer and a pharmaceutical company. Now Bionanoplus plan to launch his technology in the vaccines manufacturers market, firstly on to the PRRSV vaccines manufacturers market. It was estimated that losses due to PRRSV cost the swine industry EUR 1.5 billion per year in Europe and USD 664 million per year in the USA. SAP-Nano enables the development of unique vaccines, which are significantly more effective than conventional vaccines. Phase 1 of SME Instrument represents an opportunity to get a thorough business plan to minimize risks. The main objective is to perform a feasibility study to verify the economic viability in the vaccines manufacturers market and design a suitable business model, and the commercial, marketing and industrial strategies. The SAP-Nano proposal was presented for the first time to the 25-11-2015 call (NMP-25-2015-1-P) achieving a total score of 12,84. The lower point in the evaluation was Impact (score: 4.21). B has met potential clients in order to know the needs and requirement to develop new vaccines. The business case has also been improved. This new information has been included in this new submission of the proposal.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "SAP-NANO" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "SAP-NANO" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.2.1.5.;H2020-EU.2.1.3.;H2020-EU.2.3.1.;H2020-EU.2.1.2.)

NAS (2018)

Nexilis augmentation system

Read More  

Gri3D (2018)

The industrialization and market entry of a novel bioengineered hydrogel grid to standardize stem cell cultures for precision medicine.

Read More  

CGM (2018)

A next generation nano media tailored to capture and recycle hazardous micropollutants in contaminated industrial wastewater.

Read More